Antenatal Intracellular Concentrations of Tenofovir Diphosphate (TFV-DP) and Emtricitabine Triphosphate, and Associations between TFV-DP and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial

BACKGROUND: In the PROMISE trial, tenofovir disoproxil fumarate (TDF) use was associated with moderate or severe adverse pregnancy/neonatal outcomes. This study characterized tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP) concentrations in dried blood spots (DBS), and assesse...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Acquir Immune Defic Syndr
Auteurs principaux: Aizire, Jim, Brooks, Kristina M., Mirochnick, Mark, Flynn, Patricia M., Butler, Kevin, Kiser, Jennifer J., Siberry, George K., Fenton, Terry, Cababasay, Mae, Fowler, Mary Glenn
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7409985/
https://ncbi.nlm.nih.gov/pubmed/31929405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000002247
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires